BiotechTube
CLOVERNA

CLOVERNA

Tokyo, Japan· Est.

Cloverna is a biotech company developing oligonucleotide drugs targeting non-coding RNA for rare diseases using a proprietary CRISPR/dCas13 platform.

cloverna.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

AI Company Overview

Cloverna is a biotech company developing oligonucleotide drugs targeting non-coding RNA for rare diseases using a proprietary CRISPR/dCas13 platform.

Rare Disease

Technology Platform

Proprietary CRISPR/dCas13-based platform (DIRAC and TRIP technologies) for identifying disease-associated RNA interactions and developing selective RNA-interaction modifiers (SRiMs) targeting long non-coding RNAs.

Opportunities

Cloverna's technology could unlock a new class of oligonucleotide therapeutics targeting the vast, underexplored landscape of non-coding RNA, particularly for rare diseases with no existing treatments.
Their platform approach allows for multiple program generation across various disease areas.

Risk Factors

As an early-stage company with unproven technology, Cloverna faces significant scientific risk in validating that targeting lncRNA interactions can yield safe and effective therapeutics, along with financial risk as a pre-revenue startup requiring substantial additional funding.

Competitive Landscape

Cloverna competes in the RNA therapeutics space against established players like Alnylam (siRNA) and Ionis (ASO), but differentiates through its specific focus on lncRNA targeting using CRISPR/dCas13 technology, a less crowded niche than mRNA or siRNA approaches.

More companies in Japan →